IL255420A0 - Selective modulators of gpr55 receptor activity: chromopyrazole derivatives - Google Patents
Selective modulators of gpr55 receptor activity: chromopyrazole derivativesInfo
- Publication number
- IL255420A0 IL255420A0 IL255420A IL25542017A IL255420A0 IL 255420 A0 IL255420 A0 IL 255420A0 IL 255420 A IL255420 A IL 255420A IL 25542017 A IL25542017 A IL 25542017A IL 255420 A0 IL255420 A0 IL 255420A0
- Authority
- IL
- Israel
- Prior art keywords
- chromenopyrazole
- derivatives
- activity
- selective modulators
- gpr55 receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201530608A ES2593057B1 (es) | 2015-05-05 | 2015-05-05 | Moduladores selectivos de la actividad del receptor GPR55: derivados de cromenopirazol |
| PCT/ES2016/070314 WO2016177922A1 (es) | 2015-05-05 | 2016-04-27 | Moduladores selectivos de la actividad del receptor gpr55: derivados de cromenopirazol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL255420A0 true IL255420A0 (en) | 2017-12-31 |
Family
ID=57217626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255420A IL255420A0 (en) | 2015-05-05 | 2017-11-05 | Selective modulators of gpr55 receptor activity: chromopyrazole derivatives |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10435412B2 (https=) |
| EP (1) | EP3305794B1 (https=) |
| JP (1) | JP2018515499A (https=) |
| KR (1) | KR20180002717A (https=) |
| CN (1) | CN107735397A (https=) |
| AU (1) | AU2016257025A1 (https=) |
| BR (1) | BR112017023834A2 (https=) |
| CA (1) | CA2985021A1 (https=) |
| ES (1) | ES2593057B1 (https=) |
| IL (1) | IL255420A0 (https=) |
| MX (1) | MX2017014145A (https=) |
| RU (1) | RU2017138563A (https=) |
| WO (1) | WO2016177922A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109420174B (zh) * | 2017-08-31 | 2021-07-13 | 清华大学 | Gpr18及其调节剂在防治免疫系统疾病中的应用 |
| CN109420173B (zh) * | 2017-08-31 | 2021-07-13 | 清华大学 | Gpr55及其调节剂在防治免疫系统疾病中的应用 |
| EP4472947A1 (en) * | 2022-03-07 | 2024-12-11 | Firmenich Incorporated | Sweetener compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3624102A (en) * | 1969-05-21 | 1971-11-30 | Warner Lambert Co | Substituted benzopyranopyrazoles |
| GB0010960D0 (en) | 2000-05-05 | 2000-06-28 | Glaxo Group Ltd | Assay |
| WO2004074844A1 (en) * | 2003-02-18 | 2004-09-02 | Astrazeneca Ab | Screening assays for cannabinoid-ligand-type modulators of gpr55 |
| EP2079736B1 (en) * | 2006-12-29 | 2017-10-18 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| WO2009010824A1 (en) * | 2007-07-13 | 2009-01-22 | Glenmark Pharmaceuticals, S.A. | Dihydrochromenopyrazole derivatives as vanilloid receptor ligands |
| ES2345592B1 (es) * | 2009-03-24 | 2011-07-21 | Consejo Superior De Investigaciones Cientificas (Csic), 70% | Derivados de cromenopirazoles como ligandos de receptores de cannabinoides. |
| WO2014013117A1 (es) * | 2012-07-18 | 2014-01-23 | Consejo Superior De Investigaciones Científicas (Csic) | Cromenopirazoldionas como derivados cannabinoides de quinonas con actividad antitumoral |
| ES2548789B1 (es) | 2014-03-18 | 2016-08-08 | Consejo Superior De Investigaciones Científicas (Csic) | Nuevas cromenoquinonas moduladoras de receptores cannabinoidescb2 con actividad antitumoral |
-
2015
- 2015-05-05 ES ES201530608A patent/ES2593057B1/es not_active Expired - Fee Related
-
2016
- 2016-04-27 RU RU2017138563A patent/RU2017138563A/ru not_active Application Discontinuation
- 2016-04-27 WO PCT/ES2016/070314 patent/WO2016177922A1/es not_active Ceased
- 2016-04-27 AU AU2016257025A patent/AU2016257025A1/en not_active Abandoned
- 2016-04-27 BR BR112017023834-9A patent/BR112017023834A2/pt not_active Application Discontinuation
- 2016-04-27 MX MX2017014145A patent/MX2017014145A/es unknown
- 2016-04-27 EP EP16789355.1A patent/EP3305794B1/en active Active
- 2016-04-27 US US15/571,671 patent/US10435412B2/en active Active
- 2016-04-27 KR KR1020177034239A patent/KR20180002717A/ko not_active Withdrawn
- 2016-04-27 CN CN201680039783.1A patent/CN107735397A/zh active Pending
- 2016-04-27 JP JP2017557942A patent/JP2018515499A/ja active Pending
- 2016-04-27 CA CA2985021A patent/CA2985021A1/en not_active Abandoned
-
2017
- 2017-11-05 IL IL255420A patent/IL255420A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180201620A1 (en) | 2018-07-19 |
| JP2018515499A (ja) | 2018-06-14 |
| EP3305794A1 (en) | 2018-04-11 |
| ES2593057A1 (es) | 2016-12-05 |
| AU2016257025A1 (en) | 2017-11-30 |
| WO2016177922A1 (es) | 2016-11-10 |
| EP3305794B1 (en) | 2020-02-05 |
| EP3305794A4 (en) | 2018-11-07 |
| RU2017138563A3 (https=) | 2019-06-06 |
| BR112017023834A2 (pt) | 2018-07-31 |
| MX2017014145A (es) | 2018-06-20 |
| CA2985021A1 (en) | 2016-11-10 |
| KR20180002717A (ko) | 2018-01-08 |
| RU2017138563A (ru) | 2019-06-05 |
| ES2593057B1 (es) | 2017-09-12 |
| US10435412B2 (en) | 2019-10-08 |
| CN107735397A (zh) | 2018-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201708065B (en) | Azabenzimidazoles and their use as ampa receptor modulators | |
| IL255096A0 (en) | Ethinylestradiol as metabotropic glutamate receptor modulators | |
| ZA201605712B (en) | Therapeutic combinations with estrogen receptor modulators | |
| ZA201800827B (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators | |
| IL249267A0 (en) | Materials containing carbonitrile and their use for selective modulation of the androgen receptor | |
| EP3224261A4 (en) | Opioid receptor modulators | |
| ZA201705486B (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
| IL254921A0 (en) | Pyridopyrimidinones and their uses as nmda receptor modulators | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| IL257869A (en) | Fluoroindole derivatives as positive allosteric modulators for muscarinic receptor am.1 | |
| IL255420A0 (en) | Selective modulators of gpr55 receptor activity: chromopyrazole derivatives | |
| ZA201803520B (en) | Indane derivatives as mglur7 modulators | |
| EP3150211A4 (en) | Therapeutic agent for keratoconjunctive disorder |